Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Roche Holdings Ltd ADR (RHHBY)

Roche Holdings Ltd ADR (RHHBY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 236,591,200
  • Shares Outstanding, K 6,830,000
  • Annual Sales, $ 67,325 M
  • Annual Income, $ 12,808 M
  • 60-Month Beta 0.43
  • Price/Sales N/A
  • Price/Cash Flow 11.16
  • Price/Book 7.02
Trade RHHBY with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 02/01/24
  • Annual Dividend & Yield 0.85 (2.45%)
  • Most Recent Dividend 0.847 on 03/14/24
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
32.0400 +7.46%
on 06/03/24
35.7900 -3.80%
on 06/24/24
+2.4200 (+7.56%)
since 05/31/24
3-Month
29.2000 +17.91%
on 05/02/24
35.7900 -3.80%
on 06/24/24
+3.0500 (+9.72%)
since 04/02/24
52-Week
29.2000 +17.91%
on 05/02/24
39.9200 -13.75%
on 07/21/23
-3.7700 (-9.87%)
since 06/30/23

Most Recent Stories

More News
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:KYMR),(NASDAQ:GILD),(OTCQX:RHHBY),(NASDAQ:AMGN) EQNX::TICKER_END

ONCY : 0.9900 (-0.52%)
ONC.TO : 1.37 (+1.48%)
KYMR : 30.22 (-2.36%)
RHHBY : 34.4300 (-0.61%)
GILD : 68.40 (-0.35%)
AMGN : 310.77 (-0.08%)
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033

ONCY : 0.9900 (-0.52%)
ONC.TO : 1.37 (+1.48%)
KYMR : 30.22 (-2.36%)
RHHBY : 34.4300 (-0.61%)
GILD : 68.40 (-0.35%)
AMGN : 310.77 (-0.08%)
Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments

/CNW/ -- After looking at public health records for 3.8 million patients with invasive spreading cancer, researchers recently discovered that Generation X may...

RHHBY : 34.4300 (-0.61%)
ONCY : 0.9900 (-0.52%)
VSTM : 2.93 (-9.69%)
CADL : 6.25 (-0.79%)
FGEN : 0.7430 (-3.52%)
REGN : 1,044.66 (-1.17%)
ONC.TO : 1.37 (+1.48%)
The Fight Against Pancreatic Cancer: Biotech Firms Develop New Solutions for Rising Gen X Cases

USA News Group – After looking at public health records for 3.8 million patients with invasive spreading cancer, researchers recently discovered that Generation X may be experiencing larger per-capita...

ONCY : 0.9900 (-0.52%)
ONC.TO : 1.37 (+1.48%)
RHHBY : 34.4300 (-0.61%)
VSTM : 2.93 (-9.69%)
CADL : 6.25 (-0.79%)
FGEN : 0.7430 (-3.52%)
REGN : 1,044.66 (-1.17%)
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises

EQNX::TICKER_START (NASDAQ:TLSA),(NYSE:LLY),(OTCQX:RHHBY),(NASDAQ:BIIB),(NASDAQ:TGTX) EQNX::TICKER_END

TLSA : 0.8590 (-3.00%)
LLY : 906.71 (-0.84%)
RHHBY : 34.4300 (-0.61%)
BIIB : 228.82 (-1.27%)
TGTX : 18.31 (+0.88%)
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises

TLSA : 0.8590 (-3.00%)
LLY : 906.71 (-0.84%)
RHHBY : 34.4300 (-0.61%)
BIIB : 228.82 (-1.27%)
TGTX : 18.31 (+0.88%)
2 Cathie Wood Biotech Stocks That Could Be Worth the Risk

You don't need to buy her picks, but it's worth understanding them.

RHHBY : 34.4300 (-0.61%)
ARKK : 44.82 (+0.83%)
ARKG : 22.89 (-1.46%)
DNA : 0.3465 (+7.21%)
RXRX : 7.16 (-4.02%)
If You'd Invested $100 in Viking Therapeutics Stock 2 Years Ago, Here's How Much You'd Have Today

What would a $100 investment in Viking Therapeutics back in 2022 be worth today? Prepare to be surprised.

GS : 465.61 (+0.42%)
RHHBY : 34.4300 (-0.61%)
VKTX : 51.54 (-6.83%)
Advancements in Cancer Therapeutics: What to Expect from the Upcoming 2024 Oncology Conference

USA News Group News Commentary – As the 2024 American Society of Clinical Oncology (ASCO) annual meeting approaches, excitement builds over the latest in cancer treatment advancements, particularly in...

ONCY : 0.9900 (-0.52%)
ONC.TO : 1.37 (+1.48%)
MRK : 127.72 (-0.14%)
RHHBY : 34.4300 (-0.61%)
AMGN : 310.77 (-0.08%)
BNTX : 78.76 (-0.09%)
Pancreatic Cancer Battle Intensifies with Biotech Sector's Advanced Treatments

USA News Group – A new study is bringing hope in the fight against one of the deadliest cancers, revealing a blood test that can detect early-stage pancreatic cancer with 97% accuracy. This breakthrough...

ONCY : 0.9900 (-0.52%)
ONC.TO : 1.37 (+1.48%)
RHHBY : 34.4300 (-0.61%)
MRUS : 53.09 (-2.50%)
MGNX : 4.10 (-4.65%)
IMRX : 1.0900 (-6.84%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Basel, Switzerland-based Roche Holding Ltd. is a leading health care company focused on developing and commercializing innovative diagnostic and therapeutic products and services, which enable early detection and prevention of diseases as well as their treatment and monitoring. The company conducts its...

See More

Key Turning Points

3rd Resistance Point 34.7533
2nd Resistance Point 34.6327
1st Resistance Point 34.5313
Last Price 34.4300
1st Support Level 34.3093
2nd Support Level 34.1887
3rd Support Level 34.0873

See More

52-Week High 39.9200
Fibonacci 61.8% 35.8250
Fibonacci 50% 34.5600
Last Price 34.4300
Fibonacci 38.2% 33.2950
52-Week Low 29.2000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar